Jianhua Yu[Author] - Search Results

Year	Number of Results
2002	1
2004	5
2005	4
2006	5
2007	10
2008	11
2009	16
2010	18
2011	21
2012	23
2013	18
2014	28
2015	35
2016	37
2017	23
2018	40
2019	26
2020	31
2021	45
2022	47
2023	36
2024	6

1

The emerging field of oncolytic virus-based cancer immunotherapy.

Ma R, Li Z, Chiocca EA, Caligiuri MA, Yu J. Ma R, et al. Among authors: yu j. Trends Cancer. 2023 Feb;9(2):122-139. doi: 10.1016/j.trecan.2022.10.003. Epub 2022 Nov 17. Trends Cancer. 2023. PMID: 36402738 Free PMC article. Review.

2

YTHDF2 orchestrates tumor-associated macrophage reprogramming and controls antitumor immunity through CD8⁺ T cells.

Ma S, Sun B, Duan S, Han J, Barr T, Zhang J, Bissonnette MB, Kortylewski M, He C, Chen J, Caligiuri MA, Yu J. Ma S, et al. Among authors: yu j. Nat Immunol. 2023 Feb;24(2):255-266. doi: 10.1038/s41590-022-01398-6. Epub 2023 Jan 19. Nat Immunol. 2023. PMID: 36658237 Free PMC article.

3

N6-methyladenosine-mediated gene regulation and therapeutic implications.

Liu Y, Yang D, Liu T, Chen J, Yu J, Yi P. Liu Y, et al. Among authors: yu j. Trends Mol Med. 2023 Jun;29(6):454-467. doi: 10.1016/j.molmed.2023.03.005. Epub 2023 Apr 15. Trends Mol Med. 2023. PMID: 37068987 Review.

4

Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapy.

Ma S, Caligiuri MA, Yu J. Ma S, et al. Among authors: yu j. Trends Immunol. 2022 Oct;43(10):833-847. doi: 10.1016/j.it.2022.08.004. Epub 2022 Sep 1. Trends Immunol. 2022. PMID: 36058806 Free PMC article. Review.

5

The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation.

Liu T, Wei Q, Jin J, Luo Q, Liu Y, Yang Y, Cheng C, Li L, Pi J, Si Y, Xiao H, Li L, Rao S, Wang F, Yu J, Yu J, Zou D, Yi P. Liu T, et al. Among authors: yu j. Nucleic Acids Res. 2020 Apr 17;48(7):3816-3831. doi: 10.1093/nar/gkaa048. Nucleic Acids Res. 2020. PMID: 31996915 Free PMC article.

6

Targeting the RNA m⁶A modification for cancer immunotherapy.

Li X, Ma S, Deng Y, Yi P, Yu J. Li X, et al. Among authors: yu j. Mol Cancer. 2022 Mar 16;21(1):76. doi: 10.1186/s12943-022-01558-0. Mol Cancer. 2022. PMID: 35296338 Free PMC article. Review.

7

The Broad Spectrum of Human Natural Killer Cell Diversity.

Freud AG, Mundy-Bosse BL, Yu J, Caligiuri MA. Freud AG, et al. Among authors: yu j. Immunity. 2017 Nov 21;47(5):820-833. doi: 10.1016/j.immuni.2017.10.008. Immunity. 2017. PMID: 29166586 Free PMC article. Review.

8

Therapeutic application of human type 2 innate lymphoid cells via induction of granzyme B-mediated tumor cell death.

Li Z, Ma R, Tang H, Guo J, Shah Z, Zhang J, Liu N, Cao S, Marcucci G, Artis D, Caligiuri MA, Yu J. Li Z, et al. Among authors: yu j. Cell. 2024 Feb 1;187(3):624-641.e23. doi: 10.1016/j.cell.2023.12.015. Epub 2024 Jan 10. Cell. 2024. PMID: 38211590

9

The Notch signaling pathway: a potential target for cancer immunotherapy.

Li X, Yan X, Wang Y, Kaur B, Han H, Yu J. Li X, et al. Among authors: yu j. J Hematol Oncol. 2023 May 2;16(1):45. doi: 10.1186/s13045-023-01439-z. J Hematol Oncol. 2023. PMID: 37131214 Free PMC article. Review.

10

Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy.

Cao X, Chen J, Li B, Dang J, Zhang W, Zhong X, Wang C, Raoof M, Sun Z, Yu J, Fakih MG, Feng M. Cao X, et al. Among authors: yu j. Sci Adv. 2022 Mar 18;8(11):eabl9171. doi: 10.1126/sciadv.abl9171. Epub 2022 Mar 18. Sci Adv. 2022. PMID: 35302839 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

429 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

429 results

Results by year